Document is current
Any future updates will be listed below
-
Authors
Pereira, Joana B.
Kumar, Atul https://orcid.org/0000-0002-2166-4805
Hall, Sara https://orcid.org/0000-0001-6585-9105
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Bali, Divya
Parchi, Piero https://orcid.org/0000-0002-9444-9524
Mattsson-Carlgren, Niklas
Janelidze, Shorena
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 26 February 2023
Accepted: 1 August 2023
First Online: 18 September 2023
Competing interests
: O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy and speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.P. has acquired research support (for the institution) from ki elements/ADDF. In the past 2 years, he has received consultancy and speaker fees from Bioartic, Biogen, Cytox, Eli Lilly, Geras Solutions and Roche. The other authors declare no competing interests.
